Tech Company Financing Transactions
Judo Bio Funding Round
Atlas Venture, Droia Ventures and Alexandria Venture Investments participated in a $100 million Series A funding round for Judo Bio. This venture round was announced on 10/7/2024.
Transaction Overview
Company Name
Announced On
10/7/2024
Transaction Type
Venture Equity
Amount
$100,000,000
Round
Series A
Investors
Proceeds Purpose
The company intends to use the funds to advance the lead ligand-siRNA conjugate to the clinic and to further build its proprietary STRIKE (Selectively Targeting RNA Into KidnEy) platform.
Company Information
Company Status
Private & Independent
Industry
Life Sciences
Mailing Address
300 Technology Square, 8th Floor
Cambridge, MA 02139
USA
Cambridge, MA 02139
USA
Phone
Undisclosed
Website
Email Address
Overview
Judo Bio is pioneering oligonucleotide medicines delivered to the kidney, opening the way for new RNA medicines for systemic and renal diseases. With our STRIKE (Selectively Targeting RNA Into KidnEy) platform, we use a proprietary approach that harnesses a natural, endogenous mechanism to target oligonucleotide medicines to the kidney.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Rajiv Patni
Chief Scientific Officer
Alfica Sehgal
Vice President
Jonathan Lawrence
VP - Finance
Mary LeBlanc
Browse more venture capital transactions:
Prev: 10/7/2024: Layer venture capital transaction
Next: 10/7/2024: Larixon Classifieds venture capital transaction
Share this article
Where The Data Comes From
We do our best to document all VC transactions involving tech companies. All VC database entries reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs